Clinical-mediated discovery of pyroptosis in CD8+ T cell and NK cell reveals melanoma heterogeneity by single-cell

Ying Zhang1,2, Yun Bai3, Xiao-Xuan Ma1,2

  • 1Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.

Cell Death & Disease
|August 24, 2023
PubMed

Insights

Pyroptosis-related genes are less common in melanoma immune cells, impacting anti-melanoma immunity. This study reveals pyroptosis

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Pyroptosis, a programmed cell death pathway, influences cancer development and immunotherapy response.
  • The role of pyroptosis in melanoma is complex due to cellular heterogeneity.
  • Pyroptosis-related genes (PRGs) expression patterns in melanoma require detailed investigation.

Purpose of the Study:

  • To comprehensively analyze the single-cell transcriptome landscape of pyroptosis in melanoma.
  • To investigate the expression and localization of PRGs, particularly GZMA and GSDMB, in melanoma tissues.
  • To establish a prognostic model for melanoma based on PRGs.

Main Methods:

  • Single-cell RNA sequencing (scRNA-seq) of melanoma specimens.
  • Immunohistochemistry and multiplex immunofluorescence staining.
  • Bulk RNA sequencing and bioinformatic analysis for prognostic model construction.

Main Results:

  • Melanoma tissues showed reduced PRG expression in epidermal cells compared to normal skin.
  • PRGs, including GZMA and GSDMB, were predominantly expressed in immune cells like CD8+ T cells and NK cells.
  • Significantly lower percentages of GZMA+ CD8+ T cells and GSDMB+ CD57+ cells were found in melanoma compared to controls, indicating diminished pyroptosis capacity.
  • A prognostic risk model and nomogram demonstrated the clinical relevance of PRGs in melanoma.

Conclusions:

  • Reduced pyroptosis in melanoma is associated with a lower presence of specific immune cells.
  • Dysregulation of PRGs in immune cells may impair anti-melanoma responses.
  • PRGs hold potential as prognostic biomarkers for malignant melanoma prevention and treatment.